Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

HistoSonics, a medical device company backed by Johnson & Johnson’s venture capital arm, is exploring the possibility of a U.S. initial ...

We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best cheap stocks to ...

The Trump administration’s executive order pausing foreign aid programs has sent crash waves through relief organizations ...

In the latest trading session, Johnson & Johnson (JNJ ... world's biggest maker of health care products has risen by 0.15% in the past month, leading the Medical sector's loss of 2.46% and ...

Its Innovative Medicine division covers pharmaceuticals focusing on areas like immunology and oncology, alongside MedTech engaging in medical ... products and strategic market expansions. Johnson ...

Gabby Jones / Bloomberg / Getty Images Johnson & Johnson is scheduled to ... Analysts are cautiously optimistic about the pharmaceutical and medical device maker, with six of the 12 analysts ...

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, finds itself at a critical juncture as it navigates a complex landscape of opportunities and challenges. The company's recent performance and ...

Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of ...

In this article, we are going to take a look at where Johnson & Johnson (NYSE ... slower increases in medical care costs, and moderate rent growth. The data has renewed hopes that the Federal ...

(Reuters) - Abbott Laboratories on Wednesday forecast 2025 profit that came in line with Wall Street estimates as it expects ...